Welcome to our dedicated page for Shattuck Labs SEC filings (Ticker: STTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shattuck Labs’ fusion-protein science is fascinating—yet its SEC disclosures can be overwhelming. The company’s annual report details how the ARC® platform blocks immune checkpoints and activates costimulatory receptors, while pages of R&D spend obscure the real cash runway. If you have ever asked, “How do I read the Shattuck Labs annual report 10-K simplified?” or searched for “Shattuck Labs SEC filings explained simply,” this page was built for you.
Stock Titan’s AI-powered analysis converts technical language into plain English. Instantly surface the data that matters: Form 4 insider transactions real-time, quarterly burn rates from each Shattuck Labs quarterly earnings report 10-Q filing, and every Shattuck Labs 8-K material events explained alert the moment it hits EDGAR. Our models highlight when SL-172154 reaches a clinical milestone, flag collaboration revenue swings, and summarize risk-factor changes in seconds—so you spend time interpreting, not searching.
All filing types are here with live updates. Track Shattuck Labs insider trading Form 4 transactions to gauge management’s conviction, review the proxy statement executive compensation before voting, or dive into an earnings report filing analysis to compare trial costs quarter over quarter. Need context? Our concise AI summaries sit beside the full document, helping professionals understand complex disclosures quickly. Whether you’re monitoring Shattuck Labs executive stock transactions Form 4 or seeking a fresh lens on the annual report 10-K simplified, the intelligence you need is one click away.
Shattuck Labs, Inc. files a Form S-3 shelf registration that describes an offering including Common Stock, Pre-Funded Warrants and Common Warrants and incorporates by reference prior SEC reports and a Form 8-K filed August 5, 2025. The filing lists a detailed beneficial ownership table showing pre- and post-offering share counts and percentages for multiple investors and insiders, including a holder with 36,879,576 shares (39.35%). The document discloses a securities purchase agreement dated August 4, 2025, exhibits including certificate and bylaw amendments, forms of warrants and registration rights, legal and accounting opinions, and filing fee information. Signatures from the CEO and directors are included with dates in September 2025.
OrbiMed-affiliated entities disclosed acquiring an aggregate of 6,306,127 Shares of Shattuck Labs, representing 9.99% of the outstanding common stock on a post-PIPE basis. The holdings arise from the August 25, 2025 closing of a PIPE in which the issuer sold 15,225,158 Shares and pre-funded warrants and accompanying warrants aggregating potential issuance of 52,635,346 Shares. OrbiMed Private Investments IX, LP (OPI IX) purchased 5,255,106 Shares (≈9.99%) and OrbiMed Genesis Master Fund, L.P. (Genesis) purchased 1,051,021 Shares (≈1.67%).
The PIPE included pre-funded and common warrants but those warrants are subject to an exercise 9.99% blocker and are not presently exercisable. OrbiMed Advisors and its GP entities disclose shared voting and dispositive power over the shares held by the funds and note a board relationship via Director Mona Ashiya, who is obligated to transfer any director equity awards to OrbiMed-affiliated funds. A registration rights agreement was negotiated requiring the issuer to file a resale registration for the PIPE shares.
OrbiMed-affiliated reporting persons purchased securities of Shattuck Labs (STTK) in a private placement that closed on 08/25/2025. They acquired an aggregate of 6,306,127 shares and pre-funded warrants to buy up to 12,133,661 additional shares, plus common warrants exercisable for up to 18,439,799 shares. The price per share with a common warrant was $0.8677 and per pre-funded warrant with a common warrant was $0.8676. The pre-funded warrants are immediately exercisable subject to a 9.99% ownership blocker. Common warrants expire based on clinical-trial data disclosure timing described in the filing.
Shattuck Labs reported a private placement on 08/25/2025 in which accredited investors led by OrbiMed vehicles purchased an aggregate of 6,306,127 shares of common stock and received pre-funded warrants to buy up to 12,133,661 shares plus accompanying common warrants to buy up to 18,439,799 shares. The price per share with an accompanying common warrant was $0.8677; the pre-funded warrant price with an accompanying common warrant was $0.8676. Pre-funded warrants are immediately exercisable subject to a 9.99% beneficial ownership blocker. The report was filed by Mona Ashiya, identified as a director, who disclaims beneficial ownership of the securities except to the extent of pecuniary interest, and the securities are held of record by OrbiMed funds and related entities.
OrbiMed entities and OrbiMed Advisors LLC reported their relationship to Shattuck Labs (STTK) as directors but stated they do not beneficially own any securities of the issuer. The Form 3 lists three reporting entities at the same New York address and indicates the filing covers more than one reporting person. No non‑derivative or derivative holdings are reported.
Dr. Mona Ashiya, a director of Shattuck Labs, Inc. (STTK), was granted a stock option on 08/28/2025 allowing purchase of 66,300 shares of common stock at a $0.99 exercise price. The option vests in three equal annual installments on each of the first three anniversaries of August 28, 2025, is exercisable beginning on those vesting dates, and expires on August 28, 2035. The Form 4 reports 66,300 derivative securities beneficially owned following the transaction, filed by one reporting person and signed by an attorney-in-fact on 09/02/2025. An agreement requires the Reporting Person to transfer any securities or economic benefits from these awards to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC for allocation to OrbiMed Private Investments IX, LP.
Shattuck Labs director Dr. Daniel G. Baker received a stock option award for 66,300 shares of common stock with a $0.99 exercise price on 08/28/2025. The option vests in three equal annual installments beginning on the grant date and is exercisable through 08/28/2035, subject to continued service. The Form 4 was filed on 09/02/2025 and signed by an attorney-in-fact. The disclosure shows an executive compensation action that increases potential common shares outstanding if exercised and ties the director's future economic incentive to the company's stock performance.
Shattuck Labs insider Stephen Stout, the company's General Counsel and Corporate Secretary, acquired 12,805 shares of common stock and accompanying warrants in a private placement that closed on August 25, 2025. The combined price per share and warrant was $0.8677. The warrants allow purchase of up to 12,805 additional shares at an exercise price of $1.0846 and are exercisable from issuance until 30 days after the company publicly announces certain Phase 1 clinical trial data and the design of planned Phase 2 trial(s). Following the transaction, Stout beneficially owns 86,275 shares of common stock.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
